Drug Profile
MK 4250
Alternative Names: MK-4250Latest Information Update: 28 Feb 2021
Price :
$50
*
At a glance
- Originator Merck Sharp & Dohme
- Class Antiretrovirals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported HIV-1 infections
Most Recent Events
- 28 Feb 2021 No recent reports of development identified for phase-I development in HIV-1-infections(Monotherapy, Treatment-naive) in Germany (PO)
- 02 Nov 2018 Merck Sharp & Dohme completes a phase I trial in HIV-1 infections (Monotherapy, Treatment-naive) in Germany (PO) (NCT03351699)
- 18 Jan 2018 Phase-I clinical trials in HIV-1 infections (Monotherapy, Treatment-naive) in Germany (PO) (NCT03351699)